<DOC>
	<DOCNO>NCT02303899</DOCNO>
	<brief_summary>This phase II , monocentric study combination gemcitabine imatinib mesylate pemetrexed-pretreated patient MPM express PDGFR-beta and/or C-kit Immunohistochemistry ( IHC ) . Treatment do disease progression , patient refusal withdrawal patient consent , unacceptable toxicity</brief_summary>
	<brief_title>Combination Gemcitabine Imatinib Mesylate Pemetrexed-pretreated Patients With Pleural Mesothelioma</brief_title>
	<detailed_description>Pemetrexed-pretreated patient MPM express PDGFR-beta and/or C-kit IHC receive chemotherapy follow : - Gemcitabine 1000 mg/m2 , i.v. , day 3 10 21-days schedule ; - Imatinib mesylate 400 mg/die orally day 1-5 8-12 21-days schedule . Treatment repeat every 21 day absence disease progression , patient refusal withdrawal patient consent , unacceptable toxicity . The molecular profile patient enrol evaluated Ion Personal Genome Machine ( PGM ) Torrent Next-generation Sequencing platform order individuate potential predictive biomarkers improve understand molecular biology rare tumor . A correlation among molecular profile identify , clinical characteristic , survival data patient do</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Age &gt; 18 year . 2 . Histologically proven malignant mesothelioma pleura peritoneum , express PDGFRbeta and/or Ckit immunohistochemistry . 3 . Locally advanced disease , unsuitable curative surgical resection , metastatic disease . 4 . Confirmed progression disease accord modify RECISTcriteria , document pemetrexedbased chemotherapy . 5 . Eastern Cooperative Oncology group ( ECOG ) Performance Status 0 , 1 2 . 6 . Life expectancy least 3 month . 7 . Written informed consent . 1 . Coexisting tumor different histologic origin , except non melanomatous localized skin cancer and/or situ cervical carcinoma . 2 . A history earlier tumor different histologic origin complete remission le 5 year . 3 . Unresolved toxicity prior antitumor treatment ( ) . 4 . Primary peritoneal mesothelioma . 5 . Any following abnormal baseline hematological value : Hb &lt; 9 g/dL White blood count ( WBC ) &lt; 3 x 109/L Neutrophils &lt; 1.5 x 109/L Platelets &lt; 100 x 109/L Serum bilirubin &gt; 2.5 mg/dL Alanine transaminase ( ALAT ) Aspartate transaminase ( ASAT ) &gt; 3 x upper normal limit ( UNL ) ( unless due liver metastasis ) Serum creatinine &gt; 1.5 mg/dL . 6 . Symptomatic and/or unstable preexist brain metastasis . To enrol study , subject must confirmation stable disease MRI computer tomography ( CT ) scan within 4 week day 1 cycle 1 treatment central nervous system ( CNS ) metastases well controlled steroid , anti epileptic symptomrelieving medication . 7 . Clinically relevant cardiovascular disease , i.e. , myocardial infarction severe coronary artery disease within prior 6 month , cardiac arrythmia require medication , uncontrolled hypertension , overt cardiac failure non compensate chronic heart disease New York Heart Association ( NYHA ) class II . 8 . History psychiatric disability , potentially interfere capability give adequate inform consent . 9 . Pregnant lactate woman inability/unwillingness practice medically approve method contraception study period ( include 3 month follow end treatment ) 10 . Uncontrolled active infection . 11 . Any condition , judgement Investigator , would place patient undue risk interfere result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>